Welcome to our dedicated page for ACHIEVE LIFE SCIENCES SEC filings (Ticker: ACHV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Achieve Life Sciences SEC filings document current reports on operating results, cytisinicline development updates, governance matters, material agreements, and capital-structure disclosures. Recent Form 8-K filings include furnished financial-results releases and business updates tied to the company’s late-stage specialty pharmaceutical focus on cytisinicline for nicotine dependence.
The filing record also covers executive and board changes, compensatory arrangements, consulting and separation agreements, shareholder voting matters, security-structure disclosures, and clinical or regulatory disclosures related to the cytisinicline program. These filings provide formal records of the company’s corporate events, financial-condition updates, and governance actions as a public biotechnology issuer.
Achieve Life Sciences, Inc. director Aaron Royston reported equity compensation awards effective July 27, 2026. He received stock options for 25,000 shares at a $6.18 exercise price, expiring July 27, 2036, and 16,700 RSUs. Both awards vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual stockholders meeting, subject to continued service. The options and RSUs are held for the benefit of venBio Global Strategic Fund V, L.P., with related proceeds remitted to that fund, and Royston disclaims beneficial ownership except for his pecuniary interest.
Waldman Reid Alexander reported acquisition or exercise transactions in this Form 4 filing.
Achieve Life Sciences, Inc. director Reid Alexander Waldman received equity compensation on July 27, 2026, consisting of 25,000 stock options to buy common stock at $6.18 per share, expiring July 27, 2036, and 16,700 RSUs. Both awards vest 100% on the earlier of July 27, 2027 or immediately prior to the 2027 annual meeting, subject to continued service.
Achieve Life Sciences director Stewart Richard Alistair received equity awards on July 27, 2026: stock options for 25,000 shares at an exercise price of $6.18 per share and 16,700 RSUs, each RSU settling into one share. Both awards vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual meeting of stockholders, subject to continued service, resulting in direct holdings of 25,000 options and 16,700 RSUs. The options expire on July 27, 2036.
Achieve Life Sciences, Inc. granted director Jeffrey S. Farrow equity awards consisting of 25,000 stock options to buy common stock at an exercise price of $6.18 per share, expiring July 27, 2036, and 16,700 RSUs. Both the options and RSUs vest 100% on the earlier of July 27, 2027 or the date immediately prior to the company’s 2027 annual meeting of stockholders, subject to Farrow’s continued service.
Achieve Life Sciences director Nancy R. Phelan received new equity awards. She was granted stock options for 25,000 shares of common stock at an exercise price of $6.18 per share, expiring on July 27, 2036. These options vest 100% on the earlier of July 27, 2027 or immediately before the company’s 2027 annual stockholders’ meeting, subject to her continued service. She also received 16,700 Restricted Stock Units, each representing a contingent right to receive one share of common stock, with the same cliff-vesting schedule and service condition.
Franklin Resources, Inc. and affiliates report beneficial ownership of Achieve Life Sciences, Inc. common stock. Franklin Advisers, Inc. is reported as having sole voting and dispositive power over 8,878,942 shares, representing 8.3% of the common stock.
This position includes 3,925,722 shares issuable upon exercise of warrants. Within this holding, Franklin Biotechnology Discovery Fund has an interest in 5,670,723 shares, or 5.3% of the class. Franklin Resources, its principal shareholders, and subsidiaries disclaim pecuniary interest and do not concede they form a group for Section 13 purposes.
BlackRock, Inc. reports beneficial ownership of common stock of Achieve Life Sciences, Inc. as of June 30, 2026. BlackRock reports beneficial ownership of 5,271,391 shares of common stock, representing 5.1% of the class.
BlackRock has sole voting power over 5,188,710 shares and sole dispositive power over 5,271,391 shares, with no shared voting or dispositive power. The shares are held across certain BlackRock business units on behalf of various clients, and no single underlying person is reported to have more than five percent of Achieve Life Sciences’ outstanding common shares.
Vivo Opportunity entities report beneficial ownership of Achieve Life Sciences common stock. Collectively, Vivo Opportunity, LLC and its related funds may be deemed to beneficially own 5,305,640 shares of common stock, equal to 5.0% of the issuer on the filing's stated basis. Several related funds report holdings ranging from 196,424 shares (0.2%) to 2,140,852 shares (2.0%); totals include shares issuable on exercise of warrants and are calculated on 105,410,089 shares outstanding (including certain warrant shares) as of the filing’s stated basis.
Achieve Life Sciences, Inc. amended its certificate of incorporation to increase authorized common stock from 150,000,000 shares to 300,000,000 shares, following approval at its annual meeting of stockholders.
Stockholders elected nine directors, ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.